Active Ingredient: Atezolizumab
Atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR-mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Atezolizumab, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR-mutant or ALK-positive NSCLC.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Regimen A: Intravenous, 840 milligrams atezolizumab, once every 2 weeks.
Regimen B: Intravenous, 1,200 milligrams atezolizumab, once every 3 weeks.
Regimen C: Intravenous, 1,680 milligrams atezolizumab, once every 4 weeks.
Induction and maintenance phases:
Atezolizumab should be administered first when given on the same day.
Induction phase for combination partners (four or six cycles):
Bevacizumab, paclitaxel, and then carboplatin are administered every three weeks.
Maintenance phase (without chemotherapy):
Bevacizumab every 3 weeks.
Until disease progression or unmanageable toxicity. Atypical responses (i.e., an initial disease progression followed by tumour shrinkage) have been observed with continued atezolizumab treatment after disease progression. Treatment beyond disease progression may be considered at the discretion of the physician.
Induction and maintenance phases:
Atezolizumab should be administered first when given on the same day.
Induction phase for combination partners (four or six cycles):
Nab-paclitaxel, and carboplatin are administered on day 1; in addition, nab-paclitaxel is administered on days 8 and 15 of each 3-weekly cycle.
Until disease progression or unmanageable toxicity. Atypical responses (i.e., an initial disease progression followed by tumour shrinkage) have been observed with continued atezolizumab treatment after disease progression. Treatment beyond disease progression may be considered at the discretion of the physician.
If a planned dose of atezolizumab is missed, it should be administered as soon as possible. The schedule of administration must be adjusted to maintain the appropriate interval between doses.
Dose reductions of atezolizumab are not recommended.
The infusions must not be administered as an intravenous push or bolus.
The initial dose of atezolizumab must be administered over 60 minutes. If the first infusion is well tolerated, all subsequent infusions may be administered over 30 minutes.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
